Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Purchases 2,500 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel acquired 2,500 shares of the company’s stock in a transaction that occurred on Thursday, July 23rd. The shares were bought at an average cost of $13.14 per share, for a total transaction of $32,850.00. Following the acquisition, the chief executive officer directly owned 5,606,602 shares in the company, valued at $73,670,750.28. This represents a 0.04% increase in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Snehal Patel also recently made the following trade(s):

• On Friday, July 24th, Snehal Patel bought 1,100 shares of Greenwich LifeSciences stock. The shares were bought at an average cost of $12.88 per share, with a total value of $14,168.00.

Greenwich LifeSciences Price Performance

Shares of GLSI traded up $0.17 during midday trading on Tuesday, hitting $13.61. 80,197 shares of the company traded hands, compared to its average volume of 246,025. The stock has a 50-day moving average of $21.88 and a 200-day moving average of $24.35. Greenwich LifeSciences, Inc. has a one year low of $7.78 and a one year high of $34.10. The firm has a market cap of $199.74 million, a P/E ratio of -8.65 and a beta of 1.40.

Institutional Investors Weigh In On Greenwich LifeSciences

Institutional investors and hedge funds have recently bought and sold shares of the stock. Sei Investments Co. purchased a new stake in Greenwich LifeSciences during the first quarter valued at about $627,000. Bank of New York Mellon Corp raised its stake in shares of Greenwich LifeSciences by 235.5% during the first quarter. Bank of New York Mellon Corp now owns 46,523 shares of the company’s stock worth $1,117,000 after acquiring an additional 32,657 shares in the last quarter. Strs Ohio raised its position in Greenwich LifeSciences by 140.4% in the 1st quarter. Strs Ohio now owns 13,700 shares of the company’s stock worth $329,000 after purchasing an additional 8,000 shares during the period. Virtu Financial LLC bought a new stake in Greenwich LifeSciences in the fourth quarter worth $605,000. Finally, XTX Topco Ltd bought a new stake in Greenwich LifeSciences in the fourth quarter worth $217,000. 4.16% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on GLSI shares. HC Wainwright upped their target price on shares of Greenwich LifeSciences from $50.00 to $69.00 and gave the stock a “buy” rating in a report on Tuesday, July 21st. Wall Street Zen downgraded shares of Greenwich LifeSciences from a “hold” rating to a “sell” rating in a report on Saturday, June 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Greenwich LifeSciences in a research report on Friday, May 15th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $57.00.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.